[Drug-induced phospholipid storage disease].
D000307:Adrenal Gland Diseases / Q000139:chemically induced; D000639:Amitriptyline / Q000009:adverse effects; D000818:Animals; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D001067:Appetite Depressants / Q000009:adverse effects; D001835:Body Weight; D009202:Cardiomyopathies / Q000139:chemically induced; D055598:Chemical Phenomena; D002621:Chemistry; D002738:Chloroquine / Q000009:adverse effects; D002745:Chlorphentermine / Q000009:adverse effects; D004347:Drug Interactions; D005260:Female; D005277:Fenfluramine / Q000009:adverse effects; D006801:Humans; D007488:Iprindole / Q000009:adverse effects; D008064:Lipidoses / Q000139:chemically induced*; D008171:Lung Diseases / Q000139:chemically induced; D008247:Lysosomes / Q000187:drug effects; D008297:Male; D010743:Phospholipids / Q000096:biosynthesis / Q000378:metabolism*; D010879:Piperazines / Q000009:adverse effects; D051381:Rats; D013733:Testicular Diseases / Q000139:chemically induced; D013959:Thyroid Diseases / Q000139:chemically induced; D014308:Triparanol / Q000009:adverse effects
D000924:Anticholesteremic Agents; D001067:Appetite Depressants; D010743:Phospholipids; D010879:Piperazines; D000639:Amitriptyline; D005277:Fenfluramine; D014308:Triparanol; D007488:Iprindole; D002738:Chloroquine; D002745:Chlorphentermine
Arzneimittel-induzierte Phospholipidspeicherkrankheit.